Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in ...
Background People living with HIV (PWH) are at increased risk of cardiovascular disease; however, evidence from Asian populations remains limited. We evaluated the prevalence and characteristics of ...
A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...
A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.
Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results